KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Edwards Lifesciences (EW) Shares Outstanding (2016 - 2026)

Edwards Lifesciences has reported Shares Outstanding over the past 16 years, most recently at $580.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding fell 1.34% year-over-year to $580.7 million; the TTM value through Dec 2025 reached $580.7 million, down 1.34%, while the annual FY2025 figure was $580.7 million, 1.34% down from the prior year.
  • Shares Outstanding for Q4 2025 was $580.7 million at Edwards Lifesciences, roughly flat from $580.7 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $657.6 million in Q2 2025 and troughed at $580.7 million in Q3 2025.
  • A 5-year average of $641.3 million and a median of $646.7 million in 2022 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 5199.17% in 2021 and later decreased 11.25% in 2025.
  • Year by year, Shares Outstanding stood at $642.0 million in 2021, then grew by 0.67% to $646.3 million in 2022, then grew by 0.65% to $650.5 million in 2023, then fell by 9.52% to $588.6 million in 2024, then decreased by 1.34% to $580.7 million in 2025.
  • Business Quant data shows Shares Outstanding for EW at $580.7 million in Q4 2025, $580.7 million in Q3 2025, and $657.6 million in Q2 2025.